| TA117 |
Hyperparathyroidism - cinacalcet (TA117) |
|
-
-
chronic kidney disease
Fast, easy summary view of NICE guidance on 'chronic kidney disease'
-
-
-
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Cinacalcet is not generally recommended for treating people on dialysis who have hyperparathyroidism because of their kidney disease. However, it is recommended for people on dialysis who:
- have very high levels of parathyroid hormone in their blood that can't be lowered by other treatments, and
- cannot have an operation to remove the parathyroid glands (a parathyroidectomy), because of the risks involved.
People who do receive cinacalcet should have regular checks. Treatment should be stopped if the parathyroid hormone levels in their blood do not fall substantially within 4 months.
-
Other information
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: chronic kidney disease
How this guidance was produced
Background information
This page was last updated: 09 May 2011
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
